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Based on a comprehensive survey of 150 school-age children who suffer from bronchial asthma, there has been 
found that homozygosity for both alleles of the gene of glutathione transferase (GSTT1+ M1+) was associated with 
more frequent use both inhaled corticosteroids at 3 Step 3 of basic therapy and leukotriene modifiers as well as 
better asthma control level according to the ACT-test. Under the presence of such genotypes as GSTT1+ M1-, 
GSTT1-M1+ or GSTT1-M1-, the basic treatment was more likely within 2-nd and 4-th Steps by GINA 
recommendations, but the level of asthma control was worse in these children.  
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1. Introduction 
The primary principles of the treatment of 
bronchial asthma are reduction of the airways 
inflammation, as well as achievement and 
maintenance of control of the disease [1]. 
According to existing guidelines for asthma 
management, stepwise approach to bronchial 
asthma therapy is definitely based on indication 
of disease severity, at that, inhaled corticosteroids 
(ICS) are the main basic anti-inflammatory drugs 
[2-3]. In most cases of childhood bronchial asthma 
after receiving basic therapy by ICS, reduction of 
the frequency of symptoms and improvement of 
respiratory function are observed. But in some 
patients, especially with severe asthma, 
inefficiency of corticosteroids occurs, that leads 
to insufficient asthma control [4]. 
However, the fact that the genetic factor is a one 
of significant components playing role in asthma 
control achievement remains the undisputed [5-6], 
because it forms a specific phenotype of 
bronchial asthma and, as well, causes both 
features of responses to stimuli of the 
environment and response to drug therapy [7]. 
Some authors observed relatively less efficacy of 
corticosteroids under the polymorphism of genes 
CDH1 and SERPINE1 [8-9], but the question about 
the effectiveness of ICS based on genetic 
characteristics in children, remains uncertain. 
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It is noted that this polymorphism of genes 
encoding enzymes of the second phase of 
detoxication of xenobiotics, affect the 
functionality of these enzymes in the lungs and 
other organs, which increases genetic 
susceptibility to oxidative stress and bronchial 
asthma [10]. These genes-modifiers include such 
genes of glutathione-S-transferase (GST) as 
GSTM1, GSTT1, and at the same time the 
association of genotypes GSTT1-\ GSTM1 
increase the risk of bronchial asthma in children 
five times more compared to a population [11-12]. 
In most cases, the GST brings into detoxification 
of electrophilic substances, connecting them with 
glutathione and reducing the harmful effects of 
reactive oxygen species into essential protein 
components of cells [13]. However, research on 
the impact of the genetic components of children 
to asthma control achieve as well as 
characteristics of patients’ needs for basic anti-
inflammatory therapy are currently poorly 
understood [14-15]. 
Consequently, the aim of our research was to 
evaluate basic anti-inflammatory therapy of 
bronchial asthma in school-age patients to further 
optimization of the therapeutic approach and 
maintaining of asthma control.  
 
2. Materials and Methods  
2.1 Principle of randomization.  
By the method of simple random sampling cohort 
of 150 school-age children with bronchial asthma 
was established. At the allergological department 
of the Chernovtsy Regional Children Clinical 
Hospital (Ukraine) the complex clinical, 
laboratory and instrumental investigations was 
performed for all patients. For establishment of 
the asthma therapy efficacy depending on the 
activity of second phase of detoxification of 
xenobiotics, polymorphism of genes of 
glutathione-S-transferase family (GSTT1 and 
GSTM1) was determined by the method of 
genetically-molecular analysis.   
 
2.2 Methods for determination of 
polymorphism of GST genes  
Determination of deletions in the genes GSTM1 
and GSTT1 was conducted using multiplex 
polymerase chain reaction (PCR), and an 
amplification of fragments of BRCA1 was used 
as a positive control of successfulness of PCR.  
To visualize the DNA fragments, a gel was 
stained with ethidium bromide and then 
photogravured under ultraviolet light by the 
device GelDoc 2000 (BioRad, USA). To 
determine the length of the fragments, their 
electrophoretic mobility compared with the 
mobility of such DNA-marker as Gene Ruler 
DNA Leader Mix (Fermentas, Lithuania). 
Homozygous forms with deletion of both copies 
of genes GSTT1 and GSTM1 were identified by 
the absence of the corresponding fragment, 
visualized by the diaelectrophoresis. These 
genotypes are designated as T1- and M1-. 
Accordingly, the presence of these fragments 
testified homo- or heterozygosity by a normal 
copy of the gene. The genotype of such patients 
designated as T1+ and M1+. 
 
2.3 General characteristic of comparative 
groups of patients.  
In total cohort the genotype GSTT1+M1+ was 
observed in 69 patients (46.0%), the genotype 
GSTT1-M1+ was determined in 19 (12,7%) 
children, but the GSTT1+M1- and GSTT1-M1- 
genotypes were identified in 48 (32.0%) and 14 
(9.3%) cases correspondingly.  Based on the 
results, all of the patients were divided into two 
clinical groups. The first (I) clinical group 
consisted of 69 children with bronchial asthma, 
who did not have deletion polymorphism of the 
studied genes, and so their genotype was 
determined as GSTT1+ M1+. Theirs average age 
was 10.71±0.35 years, among them there were 48 
boys (69.6%). The second (II) comparison group 
entered 81 patients, who had deletion 
polymorphism of studied genes of detoxification 
enzymes in both homozygous and heterozygous 
variants, that were represented as GSTT1+M1-, 
GSTT1-M1+ and GSTT1-M1- genotypes. The 
number of boys in this group was 53 (65.43%), 
and mean age of patients was equal to 10.75±0.33 
years. There were no differences in place of 
residence of residence surveyed children. Thus, 
34 (49.28%) patients of the first clinical group 
and 35 (43.21%) children from the II-nd group 
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lived in the city (P>0.05). Severity of asthma was 
also corresponded on average in patients of the 
comparison groups. Thus, at the first clinical 
group persistent mild, moderate and severe 
course of the disease occurred in 7.25%, 49.28% 
and 43.48% of patients, respectively. At the 
second clinical comparison group intermittent 
asthma was registered in 1 child (1.24%), 2 
patients (2.47%) had mild persistent asthma, but 
moderate and severe course of the disease 
occurred in 46.91% and 49.39% of cases 
respectively (in all cases P>0.05). Consequently, 
the main clinical characteristics of the 
comparison groups and subgroups were 
comparable, while established minor differences 
did not affect significantly the results of the 
study, indicating so a minimal risk of systemic 
error. 
 
2.4 Principles of bronchial asthma 
management. 
Treatment of asthma conducted according to the 
GINA-2011 recommendations and the order of 
Health Ministry of Ukraine № 767. The level of 
asthma control was scored by ACT test [16, 17].  
 
2.5 Statistical Analysis  
These survey results were analyzed by the 
methods of biostatistics and clinical 
epidemiology, and using the software package 
"STATISTICA 7.0" StatSoft Inc. and Excel XP 
for Windows on a PC, by parametric and 
nonparametric methods of calculation.  
 
2.6 Compliance with bioethics.  
The survey was carried out in parallel clinical 
comparison groups formed on the basis of a 
simple randomization by the "case-control" 
method with a strict observance of the bioethical 
requirements (GCP ICH and the Helsinki 
Declaration of the World Medical Association on 
biomedical research, in which a person acts as its 
object, as well as the order of the Health Ministry 
of Ukraine № 960 of 23.09.2009).   
 
3. Results and Discussions.  
Prescribed basic anti-inflammatory treatment by 
corticosteroids was accepted by 79.1% patients of 
the first clinical group and 85.0% of patients with 
polymorphisms of studied genes (P>0.05). At 
once, 20.9% of children without GSTT1 and 
GSTM1 gene polymorphism, as well as 15.0% of 
patients of II-nd group (P>0.05) did not receive 
recommended management, and that was 
evidence of low compliance. According to step 
approach to asthma management (by GINA-2011 
recommendations) [18] prescribed treatment in 
comparison groups was distributed as follows 
(Table 1). 
 
Table 1: Stepwise approach (according to GINA-2011) for managing asthma in children of comparison groups (P±m) 
Clinical groups Number of children Step 1 Step 2 Step 3 Step 4 
І group 69 20,9±4,89 20,28±5,01 52,94±6,01 5,88±2,85 
ІІ group 81 15,0±3,96 34,72±5,34 33,36±5,3 16,92±3,83 
Р >0,05 =0,05 <0,05 =0,05 
                       Note: Р – Student's criterion.
 
So, in every second child with preserved 
functional activity of the studied genes and in 
every third patient with a deletion polymorphism 
basic therapy corresponded to Step 3 by the 
GINA recommendations. However, in patients of 
the II-nd group one and a half times more often 
low doses of ICS as well as monotherapy by 
leukotriene modifiers were used. At the same 
time, at this clinical group twice as often Step-4 
approach, that considered an active anti-
inflammatory treatment (a medium or high doses 
of ICS in combination with two other drugs from 
different groups: long-acting β2- agonists, 
antagonists of leukotriene receptor modifiers 
and/or sustained release methylxanthines), was 
used. 
However, the average daily dose of inhaled 
corticosteroids taken by representatives of 
clinical comparison group showed a trend to 
higher doses of these drugs in patients without 
deletion polymorphism of the studied genes. 
Thus, the average daily dose of ICS (by 
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beclomethasone) was 301.51±22.41 mg at the 
first group, and 265.15±20.25 mg at the 
comparison group (P>0.05).  
The qualitative distribution of usage frequency of 
low, medium and high doses of ICS in 
comparison groups given in Table 2.  
 
Table 2: The frequency of usage of equipotential (by beclomethasone dipropionate) doses of ICS as a basic asthma 
treatment in children of comparison groups (P±m) 
Clinical 
groups 
Number of 
children 
ICS were not 
used 
Low doses of 
ICS 
Medium doses of  
ICS 
High doses of  
ICS 
І group 69 20,9±4,89 29,83±5,54 36,23±5,79 13,04±4,05 
ІІ group 81 15,0±3,96 45,67±3,95 29,63±5,07 9,7±3,32 
Р >0,05 <0,05 >0,05 >0,05 
  Notes: Р – Student's criterion, ICS- inhaled corticosteroids
 
Thus, low doses of ICS were used frequently in 
asthmatic children with deletion polymorphism of 
GSTT1 and GSTM1 genes, but patients of the first 
clinical group had a tendency to predominance of 
high and medium doses of corticosteroids. 
Despite the lack of differences in the frequency of 
use of ICS during the day by children of the 
clinical groups (1.58±0.12 vs 1.6±0.1 times/day 
at the comparison groups, respectively; P>0.05), 
qualitative distribution of this index testified 
about trend towards more frequent use of these 
drugs in patients without deletion polymorphism 
of GSTT1 and GSTM1 genes. Namely, inhaled 
corticosteroids once a day were used by 17.91% 
of children in the first group and 18.75 % of II-nd 
clinical comparison group (P>0.05), twice a day -  
by 43.28% and 58.75% children, respectively (P> 
0.05 ) and three times a day – by 17.91% and 
7.5% representatives, respectively (P<0.05). 
It should be noted that combined with long-acting 
β2-agonists (LABA) therapy received 14.92% of 
the patients without the polymorphism of GSTT1 
and GSTM1 genes as well as one in four patients 
(25.0%, P=0.05) of comparison group. However, 
the doses of LABA were significantly higher 
(47.38±7.44 mg/day) at the group of children 
with the deletion polymorphism of GSTT1 and 
GSTM1 genes, compared to the representatives of 
the I-st clinical group (36.1±9.38 mg/day, P> 
0,05). 
As an additional per oral therapy asthma patients 
received sustained release theophyllines and 
antagonists of leukotriene receptors: 8.96% and 
7,46% of the children of the I-st group, 
respectively, as well as 8.64% (P>0.05) and 
3.75% (P>0.05) of the patients of comparison 
group, respectively.  
Thus, the features of the basic anti-inflammatory 
treatment of children with bronchial asthma 
asthma who have no signs of deletion 
polymorphism of GSTM1 and GSTT1 genes, are 
more aggressive (use of medium and high 
dosages of ICS - within Step 3 by GINA 
recommendations) managing of asthma and twice 
as of often usage of leukotriene modifiers as a 
complementary therapy.  
In contrast, in school-aged asthma patients under 
the presence of genotype GSTT1+M1-, GSTT1-
M1+ or GSTT1-M1-, the basic controlling therapy 
(within 2-nd and 4-th Steps by GINA) received a 
few more children. Namely, within this clinical 
group in the 1,5 times more often low doses of 
ICS or monotherapy by antagonists of leukotriene 
receptors, and twice more often the aggressive 
anti-inflammatory complex treatment (according 
to  Step 4) as well were used. These patients had 
lower doses of inhaled corticosteroids, but in 
every fourth patient ICS was combined with 
LABA, which dosage was higher than at the I-st 
comparison group.  
The average results of ACT-test, that reflected the 
level of asthma control in patients of comparison 
groups, are shown in Table 3. Despite the lack of 
statistically significant differences in average 
ACT-test results, there were marked tendency 
towards better control of the disease in children 
without deletion polymorphism of the studied 
genes. However, the qualitative distribution of the 
points sum of the controlling criteria has been 
showed that the total score of ACT-test more than  
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Table 3: Comparative assessment of asthma by ACT questionnaire in children of clinical comparison groups (M±m) 
Indices of asthma control (points) Clinical groups Р I group II group 
Children 
under 
12 years 
old 
Q 1 1,50±0,22 1,80±0,25 >0,05 
Q 2 1,17±0,48 1,8±0,29 >0,05 
Q 3 1,83±0,31 1,5±0,22 >0,05 
Q 4 2,0±0,26 1,6±0,34 >0,05 
Q for parents 1 3,17±0,31 2,5±0,43 >0,05 
Q for parents 2 3,33±0,56 2,9±0,35 >0,05 
Q for parents 3 3,5±0,22 3,5±0,27 >0,05 
Total: 16,5±2,08 15,5±1,66 >0,05 
Children 
12 years 
old and 
older 
Q 1 3,29±0,2 2,97±0,18 >0,05 
Q2 3,13±0,21 2,97±0,24 >0,05 
Q 3 3,33±0,29 3,62±0,24 >0,05 
Q 4 3,13±0,28 2,72±0,22 >0,05 
Q 5 3,21±0,24 3,1±0,14 >0,05 
Total: 16,0±0,94 15,41±0,68 >0,05 
  Note: Р – Student's criterion, Q- question.
 
20 points, which associate with controlled 
disease, was observed in 41.18% of children 
without evidence of polymorphism of GSTM1 
and GSTT1 genes, but in 57.14% of cases in the 
second group (P>0.05). At the same time, partly 
controlled asthma (total score by the ACT-test is 
16 to 19 points)  and uncontrolled asthma (total 
score less than 15 points) was identified among 
the 29.41% and 29.41% cases, respectively, at the 
I-st group as well as 38,1% (P>0.05) and 4.76% 
(P<0,05) children of the comparison group,  
respectively.  
 
4. Conclusion 
At the complex basic anti-inflammatory treatment 
of bronchial asthma, more often medium and high 
doses of inhaled corticosteroids, that correspond 
to Step 3 management approach according to 
GINA recommendations, as well as twice as often 
antagonists of leukotriene receptors, were used 
under the presence of genotype GSTT1+M1+ in 
asthma school-aged patients. Under the presence 
of genotypes GSTT1+M1-, GSTT1-M1+ or 
GSTT1-M1- stepwise managing asthma was 
within 2nd and 4th Steps (according to GINA) and 
every fourth patient used a combination of 
inhaled corticosteroids with long-acting β2-
agonists, which dosage was higher, however 
asthma control level was worse in these children. 
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